Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Post-PE Syndrome and Transcatheter Therapy
Author(s): Belén Biscotti Rodil , Juan Duarte Torres , Irene Martín de Miguel , et al Added: 3 weeks ago

Heart Failure
ESC 25: The REBOOT-CNIC Trial
Author(s): Borja Ibanez Added: 4 months ago
ESC Congress 2025 - REBOOT-MI finds that beta-blocker therapy after MI did not reduce the occurrence of adverse events in patients with LVEF greater than 40%.Dr Borja Ibanez (National Centre for Cardiovascular Research, Madrid, ES) joins us to discuss findings from REBOOT-CNIC (NCT03596385). The prospective, randomised, open-label trial investigated the benefits of long-term betablocker therapy… View more

Heart Failure

MI/ACS
Polygenic Risk Score Independently Predicts New-Onset Heart Failure
Added: 3 months ago Source:  Radcliffe Cardiology, Mirjam Boros
The global burden of heart failure (HF) remains a significant challenge for healthcare systems.² While clinical risk factors are well-established, the utility of genetic information in predicting incident HF has been less certain. A recent study investigated the ability of a heart failure polygenic risk score (HF PRS) to predict new-onset HF in individuals across the full spectrum of… View more

Heart Failure

Imaging & Diagnostics
Author(s): Julian Gillmore , Margot K Davis , Ahmad Masri , et al Added: 1 year ago
First presented at ESC 2024, this on-demand programme sees Prof Julian Gillmore (University College London, London, UK) lead a distinguished faculty compromising of Dr Ahmad Masri (Oregon Health & Science University Medical Group, Portland, US), Dr Margot Davis (University of British Columbia, Vancouver, CA), and Dr Giuseppe Vergaro (Sant’Anna, Pisa, IT).The faculty present recent epidemiological… View more

Heart Failure
Job title: Nephrology and Hypertension Specialist
Dr Erika Jones is Associate Professor in the Division of Nephrology and Hypertension at the University of Cape Town and Groote Schuur Hospital in Cape Town, SA.Dr Jones interests areparticularly in hypertension, having done her PhDin this area.One of the aspects of hypertension that she is studying currently and which is of major concern to nephrologists in Cape Town, is the rising incidence of… View more
ESC 23 Late-Breaker Discussion: The RECORD MI Registry
Author(s): Harriette Van Spall , Javed Butler Added: 2 years ago
ESC 23 - Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Javed Butler (University of Mississippi Medical Center, US) to discuss the findings from the RECORD MI Registry. Recurrent myocardial infarction (MI) and new onset heart failure (HF) are major adverse complications in patients post-MI. Advances have been made for systems of care, coronary… View more

Heart Failure

Prevention & Chronic Conditions
STEP: Early Intensive BP Control Shows Long-Term Benefit
Added: 2 months ago Source:  Radcliffe Cardiology
New long-term data from the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial suggests that sustained, intensive blood pressure (BP) control provides greater cardiovascular benefits compared to a delayed approach in older patients with hypertension.¹ The findings also indicate that the earlier intensive treatment is initiated, the greater the reduction in… View more

Demographic

Heart Failure
ESC HFA 25: SCD-PROTECT
Author(s): Johann Bauersachs Added: 7 months ago
ESC HF 25 - SCD-PROTECT shows high risk of sudden cardiac arrest (SCA) and sudden cardiac death (SCD) during early medical therapy optimization for reduced LVEF in patients with new non-ischemic cardiomyopathy or MI/CAD.Prof Johann Bauersachs (Hannover Medical School, Hannover, DE) discusses findings from the SCD–PROTECT study, an investigation of sudden cardiac arrest in patients with newly… View more

Heart Failure

MI/ACS
EMPA-KIDNEY: Empagliflozin in Patients with Chronic Kidney Disease
Author(s): William Herrington Added: 1 year ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Comparison of Haemodynamic Responses to Landiolol Versus Esmolol
Author(s): Georgios Koukoulitsios , Kyriaki Tsikritsaki , Georgios Magklaras , et al Added: 7 months ago

Heart Failure

Vascular Disease and Surgery